LA HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
A subsidiary of billionaire Patrick Soon-Shiong’s NantWorks health care technology company has secured $100 million in equity funding, according to regulatory filings.
An appeals court has blocked sales of Zarxio, a copycat version of Amgen Inc.’s blockbuster drug Neupogen.
Tutor Perini Corp. Gets $56.3 Million Contract Tutor Perini Corp. has won a $56.3 million contract from Amtrak for the Hudson Yards project in New York City.
The Los Angeles Biomedical Research Institute announced Wednesday it had received its biggest ever donation: a $3 million contribution to help build a new research facility.
A Hawthorne woman has been sentenced for submitting more than $7 million through her company in fraudulent claims to Medicare primarily for power wheelchair that patients did not need.
City Attorney Mike Feuer has filed a lawsuit against Gardens Regional Hospital and Medical Center Inc. for alleged patient dumping on Skid Row.
A fat-dissolving drug from Kythera Biopharmaceuticals Inc. that reduces double chins was approved by the Food and Drug Administration Wednesday.
Anthem Blue Cross on Monday showed off a $1.1 million landscaping project at its Woodland Hills offices that replaced an expansive lawn with drought-tolerant plants.
USC Keck School of Medicine said it would eliminate 92 positions across the organization.
The California Nurses Association is calling on more than 2,400 nurses to strike Providence Health and Services hospitals in Santa Monica and Torrance and at Kaiser Permanente’s Los Angeles Medical Center next week over staffing levels and retention rates.
Fledgling life science incubator Lab Launch Inc. has signed a lease for almost 11,000 square feet in the heart of Monrovia.
The president of Anthem Blue Cross in California is leaving the insurer for a different gig in the health care industry.
Shares of biopharmaceutical company Arrowhead Research Corp. rose 1.1 percent to $8 Monday on news that the Food and Drug Administration has greenlit a new clinical study of the Pasadena firm’s most advanced drug candidate.
Medbox Climbs Medbox Inc. shares jumped 17 percent on Friday to $1.65 after the West Hollywood marijuana dispensing firm filed its first annual report and first regulatory filing since restating previous years’ financials.
Every week the Los Angeles Business Journal asks readers their views on a variety of business and economic issues. A running tally is available on the site and later will be published in the Commentary section of our print edition. Our latest poll is available on the bottom right column of our home page.